Bextra, the pain reliever manufactured by Pfizer, has been taken off the market in the United States upon the recommendation of the Food and Drug Administration. Similar drugs that are in the same class as Bextra will now carry the strongest warning labels to warn consumers about the increased risk of heart attacks and strokes.

The FDA also said that a serious skin condition could result from taking Bextra and according to Pfizer, that is the reason their pain reliever was singled out. Health officials in the European Union have also banned Bextra.

'Today's actions protect and advance the health of the millions of Americans who rely on these drugs every day,' Dr. Steven K. Galson, acting director of FDA's Center for Drug Evaluation and Research told the Associated Press.

Pfizer released a statement Thursday saying, 'For now, patients should stop taking Bextra and contact their physicians about appropriate treatment options.'

Pfizer also announced that it disputed the FDA's findings that the risks of Bextra outweigh the benefits. 'Pfizer respectfully disagrees with FDA's position regarding the overall risk-benefit profile of Bextra,' the company said.

A further investigation into the risks associated with the drug will be conducted by the FDA. But for now, Bextra is not available in the United States.